Search Results - "Bexon, Alice S."

A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation by Daniel, Weston L, Lorch, Ulrike, Mix, Scott, Bexon, Alice S

“…Tumor immunotherapy is designed to control malignancies through the host immune response but requires circumventing tumor-dysregulated immunomodulation through…”
Get full text

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1 by Boyer, Thomas D., Sanyal, Arun J., Garcia‐Tsao, Guadalupe, Regenstein, Frederick, Rossaro, Lorenzo, Appenrodt, Beate, Gülberg, Veit, Sigal, Samuel, Bexon, Alice S., Teuber, Peter

“…The development of hepatorenal syndrome type 1 (HRS1) is associated with a poor prognosis. Liver transplantation improves this prognosis, but the degree of the…”
Get full text

Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers by Cottu, Paul H, Bonneterre, Jacques, Varga, Andrea, Campone, Mario, Leary, Alexandra, Floquet, Anne, Berton-Rigaud, Dominique, Sablin, Marie-Paule, Lesoin, Anne, Rezai, Keyvan, Lokiec, François M, Lhomme, Catherine, Bosq, Jacques, Bexon, Alice S, Gilles, Erard M, Proniuk, Stefan, Dieras, Veronique, Jackson, David M, Zukiwski, Alexander, Italiano, Antoine

“…Onapristone is a type I progesterone receptor (PR) antagonist, which prevents PR- mediated DNA transcription. Onapristone is active in multiple preclinical…”
Get full text

Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: Relationship of serum creatinine to hemodynamics by Boyer, Thomas D, Sanyal, Arun J, Garcia-Tsao, Guadalupe, Blei, Andres, Carl, Daniel, Bexon, Alice S, Teuber, Peter

“…Background & Aims Administration of terlipressin plus albumin is effective in reversing type 1 HRS as compared to albumin alone. However, only about 1/3 of…”
Get full text

Onapristone Extended Release: Safety Evaluation from Phase I–II Studies with an Emphasis on Hepatotoxicity by Lewis, James H., Cottu, Paul H., Lehr, Martin, Dick, Evan, Shearer, Todd, Rencher, William, Bexon, Alice S., Campone, Mario, Varga, Andrea, Italiano, Antoine

“…Introduction Antiprogestins have demonstrated promising activity against breast and gynecological cancers, but liver-related safety concerns limited the…”
Get full text

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy by Smith, David A., Conkling, Paul, Richards, Donald A., Nemunaitis, John J., Boyd, Thomas E., Mita, Alain C., de La Bourdonnaye, Guillaume, Wages, David, Bexon, Alice S.

“…Background IMO-2055 is a Toll-like receptor 9 (TLR9) agonist that potentially enhances the efficacy of antitumor agents through immune stimulation. The…”
Get full text

Phase 1b study results of IMO-2055, a novel TLR9 agonist, in combination with erlotinib (E) and bevacizumab (bev) in patients (pts) with advanced or metastatic non-small cell lung cancer (NSCLC) who have progressed following prior chemotherapy by Smith, David A, Conkling, Paul, Richards, Donald A, Flores, Maria Regina C, Nemunaitis, John J, Boyd, Thomas E, Mita, Alain C, de La Bourdonnaye, Guillaume, Wages, David, Bexon, Alice S

Get full text

Abstract CT044: AST-008, a TLR9 agonist spherical nucleic acid, activated NK cells, T cells, and cytokines in healthy subjects in a Phase I clinical trial by Daniel, Weston L., Lorch, Ulrike, Coates, Simon, Bexon, Alice S., Mix, Scott

“…Abstract Background Exicure develops spherical nucleic acid (SNA) constructs, which are 3-dimensional arrangements of oligonucleotides where the nucleic acids…”
Get full text

Abstract LB-140: Phase 1b/2 study of an intratumoral TLR9 agonist spherical nucleic acid (AST-008) and pembrolizumab: Evidence of immune activation by Milhem, Mohammed M., Perez, Cesar A., Hanna, Glenn J., Wise-Draper, Trisha M., Bhatia, Shailender, Bexon, Alice S., Daniel, Weston L., O'Day, Steven J.

“…Abstract Background: AST-008 is a novel spherical nucleic acid configuration of a toll-like receptor 9 (TLR9) agonist oligonucleotide, designed to trigger…”
Get full text

Abstract OT2-01-01: Phase 1 study of ST101, a first-in-class peptide antagonist of CCAAT/enhancer-binding protein β (C/EBPβ), in patients with advanced solid tumors, with a phase 2 expansion in patients with hormone receptor positive breast cancer (HR+ BC) by Bexon, Alice S, Arkenau, Hendrik-Tobias, Evans, Jeff, Falchook, Gerald S, Symeonides, Stefan N, McKean, Meredith A, Fontana, Elisa, Bupath, Manojkumar, McLaren, Alistair, Chandana, Sreenivasa, Ding, Tze-en, Lim, Emerson A, Rotolo, Jim, Capiaux, Gina, Michel, Rob, Kaesshaefer, Stephen, Lakhani, Nehal J

“…Abstract Background: CCAAT/Enhancer Binding Protein Beta (C/EBPβ) is a transcription factor that is active during embryofetal development but held in an…”
Get full text

Abstract P06-03: ST101, a peptide targeting oncogenic transcription factor C/EBPβ: initial safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) data from an ongoing phase 1 dose escalation study in patients with advanced, metastatic solid tumors by Lakhani, Nehal J., Arkenau, Hendrik-Tobias, Symeonides, Stefan N., Evans, Jeffry, McKean, Meredith A., Fontana, Elisa, Bupath, Manojkumar, McLaren, Alistair, Chandana, Sreenivasa, Ding, Tze-en, Lim, Emerson A., Rotolo, Jim, Capiaux, Gina, Michel, Rob, Kaesshaefer, Stephen, Bexon, Alice S., Falchook, Gerald S.

“…Abstract Introduction: The oncogenic transcription factor CCAAT/enhancer-binding protein β (C/EBPβ) is normally active in embryofetal development, but inactive…”
Get full text

Abstract CT051: Preliminary correlative and clinical data from a first-in-human (FIH) study of the intratumoral (IT) oncolytic virotherapy, Voyager-V1, in patients with solid tumors by Powell, Steven, Patel, Manish R., Merchan, Jaime R., Cripe, Timothy P., Strauss, James, Diaz, Rosa M., Packiriswamy, Nandakumar, Brunton, Bethany A., Upreti, Deepak, Khan, Rehan, Suksanpaisan, Lukkana, Vandergaast, Rianna, Russell, Stephen J., Bexon, Alice S., Peng, Kah Whye

“…Abstract Introduction Voyager-V1TM is derived from VSV, a bullet-shaped negative sense RNA virus with very low human seroprevalence; it is engineered to…”
Get full text

Abstract 1646: Synthesis of [11C]onapristone for clinical investigation by Madar, Olivier, Fouque, Julien, Proniuk, Stefan, Rezai, Keyvan, Huguet, Samuel, Zukiwski, Alexander, Gilles, Erard M., Bexon, Alice S., Lokiec, François

“…Abstract Background: Onapristone is a type I anti-progestin, which prevents the progesterone receptor (PR) monomers from dimerizing, inhibits ligand-induced…”
Get full text

Abstract 4636: Pharmacokinetic (PK) food effect study of immediate-release onapristone and its primary metabolite (M1) in healthy female subjects: implications for design of a new formulation by Rezai, Keyvan, Proniuk, Stefan, Zukiwski, Alex, Gilles, Erard, Chassard, Didier, Denot, Caroline, Ramos, Haydee L., Bexon, Alice S., Lokiec, François

“…Abstract Introduction: Onapristone is an antiprogestin with demonstrated clinical activity in breast cancer, reported to have a t1/2 between 2 and 4 hours…”
Get full text

Mature Results of a Phase 1-2 Open-Label, Dose-Escalation Study of Intravenous SNS01-T in Patients (pts) with Relapsed or Refractory B-Cell Malignancies by Siegel, David S., McDonald, Andrew, Novitzky, Nicolas, Bensinger, William, Craig, Michael, van Rhee, Frits, Gutierrez, Martin, Libby, Edward N., Thompson, John, Bexon, Alice S, Barranco, Charles, Taylor, Catherine A, Dondero, Richard, Browne, Leslie J., Kurman, Michael R., Lust, John A.

“…Background Eukaryotic translation initiation factor 5A (eIF5A) has been implicated in the regulation of cell proliferation, apoptosis, and inflammation…”
Get full text

Pharmacokinetic (PK) and Pharmacodynamic (PD) Results of a Novel, First-in-Class Modulator of Eukaryotic Translation Initiation Factor 5A (eIF5A) in Patients (pts) with Relapsed or Refractory B-Cell Malignancies: Data from a Phase 1-2 Study by Bexon, Alice S, Craig, Michael, Siegel, David S., Bensinger, William, Novitzky, Nicolas, McDonald, Andrew, Gutierrez, Martin, Libby, Edward N., van Rhee, Frits, Heidel, Jeremy, Thompson, John, Barranco, Charles, Taylor, Catherine A, Donovan, Kathleen A., Moon-Tasson, Laurie L., Browne, Leslie J., Kurman, Michael R., Lust, John A., Dondero, Richard

“…Introduction eIF5A is the only known protein to be modified by hypusination and is highly conserved across species. Hypusinated eIF5A, the predominant form in…”
Get full text

Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1: Posttransplant Survival For HRS1 by Boyer, Thomas D., Sanyal, Arun J., Garcia-Tsao, Guadalupe, Regenstein, Frederick, Rossaro, Lorenzo, Appenrodt, Beate, Gülberg, Veit, Sigal, Samuel, Bexon, Alice S., Teuber, Peter

Get full text